Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab

Subjects

Abstract

Single-nucleotide polymorphisms (SNPs) related to hereditary thrombophilia were investigated as risk factors for thromboembolism in cancer patients. Their effect in metastatic colorectal cancer (mCRC) has never been explored so far. Our aim was to analyse the effect of coagulation factor V (FVL G1691A), prothrombin (PT G20210A), methylenetetrahydrofolate reductase (MTHFR C677T and A1298C) and plasminogen activator inhibitor type 1 (PAI-1 5G/4G) allelic variants in this setting. Fifty-two patients treated with first-line chemotherapy plus bevacizumab who developed a thromboembolic event in their lifetime were initially genotyped. A contemporary cohort of 127 patients who did not experience any thromboembolic event was also analysed. DNA was extracted from peripheral blood and genotypes were determined by real-time PCR, using LightSNiP (TIB MOLBIOL) on LightCcler 480 (Roche). The association between thromboembolism and SNPs was investigated by univariable and multivariable analyses. All SNPs were in Hardy–Weinberg equilibrium (χ2 test P>0.20). FVL G1691A and PT G20210A were present only in heterozygosis in 4 (2.2%) and 7 (3.9%) patients, respectively; MTHFR C677T in homozygosis in 29 (16.2%), MTHFR A1298C in homozygosis in 13 (7.3%); PAI-1 5G/4G in 98 (54.7%) and 4G/4G in 41 (23%) patients. At univariable analysis, treatment duration was significantly associated with thromboembolism (P<0.001), whereas gender, age, obesity, platelets count and chemotherapy backbone were not. Similarly, FVL G1691A and PT G20210A as well as MTHFR C677T and PAI-1 4G allele were significantly associated, whereas MTHFR A1298C was not. At multivariable model including PT G20210A, MTHFR C677T and PAI-1 4G (age, obesity, treatment duration and chemotherapy backbone were included as adjustment factors), the three SNPs were significantlty associated with higher risk of thromboembolism (P=0.025, <0.0001 and P=0.033, respectively). Further validation studies are warranted in order to design a prospective trial of thromboprophylaxis in mCRC patients with high-risk genotypes.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2

References

  1. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE . Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60–68.

    Article  Google Scholar 

  2. Martinelli I, De Stefano V, Mannucci PM . Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 2014; 11: 140–156.

    CAS  Article  Google Scholar 

  3. Bertina RM, Rosendaal FR . Venous thrombosis—the interaction of genes and environment. N Engl J Med. 1998; 338: 1840–1841.

    CAS  Article  Google Scholar 

  4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM . A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–3703.

    CAS  PubMed  Google Scholar 

  5. Franco RF, Reitsma PH . Genetic risk factors of venous thrombosis. Hum Genet. 2001; 109: 369–384.

    CAS  Article  Google Scholar 

  6. Miranda-Vilela AL . Role of polymorphisms in factor V (FV Leiden), prothrombin, plasminogen activator inhibitor type-1 (PAI-1), methylenetetrahydrofolate reductase (MTHFR) and cystathionine â-synthase (CBS) genes as risk factors for thrombophilias. Mini Rev Med Chem 2012; 12: 997–1006.

    CAS  Article  Google Scholar 

  7. Cattaneo M . Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006; 32: 716–723.

    CAS  Article  Google Scholar 

  8. Eldibany MM, Caprini JA . Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007; 131: 872–884.

    CAS  PubMed  Google Scholar 

  9. Lievers KJ, Boers GH, Verhoef P, den Heijer M, Kluijtmans LA, van der Put NM et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship toMTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med (Berl) 2001; 79: 522–528.

    CAS  Article  Google Scholar 

  10. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T . The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 468–477.

    CAS  Article  Google Scholar 

  11. Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A . Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851–1855.

    CAS  Article  Google Scholar 

  12. Decousus H, Moulin N, Quenet S, Bost V, Rivron-Guillot K, Laporte S et al. Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res 2007; 120: 51–61.

    Article  Google Scholar 

  13. Al-Shamsi HO, Al Farsi A, Anjum M, Shen H, Zbuk K, Cook RJ et al. Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. J Gastrointest Oncol 2015; 6: 274–279.

    PubMed  PubMed Central  Google Scholar 

  14. Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K et al. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol 2010; 27: 807–814.

    CAS  Article  Google Scholar 

  15. Khan S, Dickerman JD . Hereditary thrombophilia. Thromb J 2006; 4: 15.

    Article  Google Scholar 

  16. Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ . Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 1996; 101: 406–412.

    CAS  Article  Google Scholar 

  17. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B . Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91–96.

    CAS  Article  Google Scholar 

  18. Ravin AJ, Edwards RP, A Krohn M, Kelley JR, Christopherson WA, Roberts JM . The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 2002; 100: 1285–1289.

    CAS  PubMed  Google Scholar 

  19. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004; 10: 1312–1317.

    CAS  Article  Google Scholar 

  20. Ramacciotti E, Wolosker N, Puech-Leao P, Zeratti EA, Gusson PR, del Giglio A et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 2003; 109: 171–174.

    CAS  Article  Google Scholar 

  21. Kennedy M, Andreescu AC, Greenblatt MS, Jiang H, Thomas CA, Chassereau L et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol 2005; 128: 386–388.

    CAS  Article  Google Scholar 

  22. Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010; 21: 871–876.

    Article  Google Scholar 

  23. Ozkan M, Sivgin S, Kocyigit I, Emirogullari F, Dikilitas M, Kaynar L et al. Do thrombophilic gene mutations have a role on thromboembolic events in cancer patients? Asia Pac J Clin Oncol 2012; 8: 34–41.

    Article  Google Scholar 

  24. Eroglu A, Ulu A, Cam R, Kurtman C, Akar N . Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis 2007; 23: 31–34.

    CAS  Article  Google Scholar 

  25. Eroglu A, Egin Y, Cam R, Akar N . The 19- bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis. Ann Hematol 2009; 88: 73–76.

    CAS  Article  Google Scholar 

  26. Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, Lohse P et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002; 94: 3120–3126.

    CAS  Article  Google Scholar 

  27. Lipay NV, Dmitriev VV, Borisenok MB . Thrombotic complications during cancer treatment in children. Exp Oncol 2007; 29: 231–235.

    CAS  PubMed  Google Scholar 

  28. Blom JW, Doggen CJ, Osanto S, Rosendaal FR . Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722.

    CAS  Article  Google Scholar 

  29. Eroglu A, Ulu A, Akar N . Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis. J Thromb Thrombolysis 2006; 22: 111–112.

    Article  Google Scholar 

  30. Wang J, Wang C, Chen N, Shu C, Guo X, He Y et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venousthromboembolism: a meta-analysis. Thromb Res 2014; 134: 1241–1248.

    CAS  Article  Google Scholar 

  31. Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ et al. Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Thromb Res 2015; 136: 865–869.

    CAS  Article  Google Scholar 

  32. Ferroni P, Palmirotta R, Riondino S, De Marchis ML, Nardecchia A, Formica V et al. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. Thromb Haemost 2015; 115: 143–151.

    PubMed  Google Scholar 

  33. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H . Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol 2011; 29: 1722–1727.

    CAS  Article  Google Scholar 

  34. Khorana AA, Connolly GC . Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839–4847.

    CAS  Article  Google Scholar 

  35. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA . Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–1850.

    Article  Google Scholar 

  36. Mandalà M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007; 18: 1660–1665.

    Article  Google Scholar 

  37. Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL . Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990; 65: 425–432.

    CAS  Article  Google Scholar 

  38. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130–2135.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F Pietrantonio.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Falvella, F., Cremolini, C., Miceli, R. et al. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics J 17, 331–336 (2017). https://doi.org/10.1038/tpj.2016.22

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2016.22

Search

Quick links